Risk factor of liver disorders caused by flutamide - Statistical analysis using multivariate logistic regression analysis

Acta Urologica Japonica

Volumn 45, Issue 8, 1999, Pages 521-526

  Wada, Tetsuro ^a   Ueda, Masataka ^a   Abe, Kazuhiro ^a   Kobari, Toshihiko ^b   Yamazaki, Haruki ^b   Nakata, Joujirou ^c   Ikemoto, Isao ^d   Ohishi, Yukihiko ^d   Aizawa, Yosio ^d  

^a Fuji City General Hospital   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d JIKEI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Adverse effect; Flutamide; Liver disorder; Prostate cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIANDROGEN; FLUTAMIDE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ARTICLE; BODY MASS; HUMAN; LIFESTYLE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROSTATE CARCINOMA; REGRESSION ANALYSIS; RISK FACTOR; STATISTICAL ANALYSIS;

ALANINE TRANSAMINASE; ANDROGEN ANTAGONISTS; FLUTAMIDE; HUMANS; INCIDENCE; LIFE STYLE; LIVER DISEASES; MALE; MULTIVARIATE ANALYSIS; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RISK FACTORS;

EID: 0032836916     PISSN: 00181994     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Akaza H, Usami M, Kotake T, et al.: A randomized phase II trial of flutamide vs. chlormadinone acetate in previously untreated advanced prostatic cancer. Jpn J Clin Oncol 23: 178-185, 1993
2. Wysowski DK and Fourcroy JL: Flutamide Hepatotoxicity. J Urol 155: 209-212, 1996
3. Berson A, Wolf C, Chachaty C, et al. : Metabolic activation of nitroaromatic antiandrogen fiutamide by rat and human cytochromes P-450, including forms belonging to the 3A and 1A subfamilies. J Pharmacol Exp Ther 265: 366-372, 1993
4. Shet MS, Mcphaul M, Fisher CW, et al.: Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab Dispos Biol Fate Chem 25: 1298-1303, 1997